The trajectory of Sildenafil presents a interesting case for stakeholders in the pharmaceutical sector. While initially a tremendous success, generating billions, the exclusivity expiration and the subsequent flood of cheaper competitors have drastically impacted earnings. This raises questions about the long-term viability of analogous drug develo